When COO Joy M. Nassif was appointed CEO of Infinity Bio, Inc., investors gave her the directive to take the company to the next level, and quickly.
Infinity Bio had developed cutting-edge antibody reactome profiling technology, but its brand identity and online presence needed to reflect its sophistication and market potential.
Developed at Johns Hopkins University in Dr. H. Benjamin Larman’s Laboratory of Precision Immunology, Infinity Bio’s MIPSA technology builds on decades of work in genomics, proteomics, immunology, and bioinformatics—and they were ready for prime time.